MOG and adult T-cell leukemia/lymphoma: These results aligned with a retrospective analysis of 39 transplant-ineligible patients with untreated aggressive ATLL, where administration of first-line MOG increased the four-year OS probability by 26.3% compared to patients who only received chemotherapy (46.3% vs. 20.6%) [33].